



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Applicant : Jorg J. Goronzy et al.
 Serial No. : 09/723,000
 Filed : November 27, 2000
 Title : METHODS AND MATERIALS FOR EVALUATING RHEUMATOID ARTHRITIS

Art Unit : 1648
 Examiner : Stacy Brown

JUN 18 2002

TECH CENTER 1600/2900

U.S. Patent and Trademark Office
 Box Sequence, P.O. Box 2327
 Arlington, VA 22202


RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
 FOR PATENT APPLICATIONS CONTAINING
 NUCLEOTIDE AND/OR AMINO ACID SEQUENCES

In response to the communication dated April 4, 2002 (copy enclosed), Applicants respectfully submit the following. While claims 58 and 59 recite that the polymorphism includes the recited HLA-DRB1 alleles, these claims do not present any nucleotide or amino acid sequences as defined in 37 C.F.R. § 1.821. Thus, no sequence identifiers are required in claims 58 and 59. In addition, Applicants' specification is in compliance with 37 C.F.R. §§ 1.821-1.825 since all presented nucleic acid and amino acid sequences meeting the definition set forth in § 1.821 are properly identified with sequence identifiers.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: June 4, 2002


 J. Patrick Finn III, Ph.D.
 Reg. No. 44,109

Fish & Richardson P.C., P.A.
 60 South Sixth Street, Suite 3300
 Minneapolis, MN 55402
 Telephone: (612) 335-5070
 Facsimile: (612) 288-9696
 60088570.doc


CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

June 4, 2002


Date of Deposit

Signature



Judy Wasilkus

Typed or Printed Name of Person Signing Certificate



Application No.: 09/723,000

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: Claims 58-59 must be referenced by a SEQ ID NO.

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

TECH CENTER 1600/2900

JUN 18 2002

RECEIVED